Celgene feedback on Pomalyst suggest robust uptake, says JPMorgan

theflyonthewall.com

JPMorgan's physician feedback indicates robust uptake for Pomalyst and more positive than expected. As a result, the firm raised estimates and reiterates its Overweight rating and $115 price target.

View Comments (0)